Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CLD-101 by Calidi Biotherapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
SNV by Calidi Biotherapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
SNV is under clinical development by Calidi Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
CLD-101 by Calidi Biotherapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
CLD-101 by Calidi Biotherapeutics for Anaplastic Oligoastrocytoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Anaplastic Oligoastrocytoma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for High-Grade Glioma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for Oligodendroglioma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I...
CLD-101 by Calidi Biotherapeutics for Anaplastic Astrocytoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...
CLD-101 by Calidi Biotherapeutics for Gliosarcoma: Likelihood of Approval
CLD-101 is under clinical development by Calidi Biotherapeutics and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Calidi Biotherapeutics's NNV1?
NNV1 is an oncolytic virus commercialized by Calidi Biotherapeutics, with a leading Phase I program in Recurrent Glioblastoma Multiforme (GBM)....